Abstract
Objective To investigate the anticancer effect of the immunotoxin DTATEGF in vitro and in vivo when delivered in mouse model of a human metastatic breast cancer brain tumors.Methods The effects of the immunotoxin were tested for their ability to inhibit the proliferation of 231Br cell line in vitro by methyl thiazol tetrazolium (MTT) assay.In vivo,2 μg of DTATEGF or control Bickel3 was givenby intraperitoneal injection to nude mice with established 231 Br xenografts on their flanks,tumor volumes were measured.On a xenograft intracranial model,1 μg of DTATEGF or control Bickel3 was delivered intracranially,the bioluminescent imaging was performed and Kaplan-Meier survival curves were generated.Results In vitro,DTATEGF could kill 231Br-luc cells and showed an 50％ inhibitory dose (IC50) less than 0.01 nmol/L.In vivo,DTATEGF significantly inhibited the growth of 231Br flank tumors (P ＜0.05),mice with intracranial tumors were treated was successful in providing a survival benefit significantly prolonged relative to controls (87 vs.58 days,P ＜0.01).Conclusion DTATEGF kills the 231Br-luc cell line in vitro,and it is highly efficacious against human metastatic breast cancer brain tumors. Key words: Immunotherapy; Breast carcinoma; Metastatic brain tumors; Model,animal
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
